AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17321923 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with fentanyl 1 microg.kg‐1 IV and 1.0 mg.kg‐1 propofol (F/P group, n=40)
Number of subjects: 80
Study 15646652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous iron supplement (Ferall, a combination of ferrous fumarate with ascorbic acid, folic acid, and cyanocobalamin)
Number of subjects: 72
Study 15646652 — intervention group
Group type: COMPARATOR
Intervention: Ferric iron polysaccharide complex (Niferex, ferro‐glycine sulfate) plus ascorbic acid
Number of subjects: 72
Study 15646652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both supplements
Number of subjects: 72
Study 11468148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine alone
Number of subjects: 388
Study 11468148 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine and mitoxantrone
Number of subjects: 388
Study 9886204 — intervention group
Group type: EXPERIMENTAL
Intervention: Home chlorination intervention
Number of subjects: 1583
Study 9886204 — intervention group
Group type: COMPARATOR
Intervention: No piped water (control group)
Number of subjects: 1583
Study 9886204 — intervention group
Group type: COMPARATOR
Intervention: Piped water (control group)
Number of subjects: 1583
Study 8092577 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 min of 100% O2 (Group A, n = 12)
Number of subjects: 27
Study 8092577 — intervention group
Group type: COMPARATOR
Intervention: 4 maximally deep inspirations of 100% O2 (Group B, n = 15)
Number of subjects: 27
Study 3139571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 250 mg mixed testosterone esters at 2-week intervals
Number of subjects: 15
Study 3139571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate 120 mg bd
Number of subjects: 15
Study 3139571 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone pellets (6 x 100 mg)
Number of subjects: 15
Study 30204486 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic HCL with enhancements
Number of subjects: 12
Study 30204486 — intervention group
Group type: COMPARATOR
Intervention: Medtronic standard HCL algorithm (Control)
Number of subjects: 12
Study 28126447 — intervention group
Group type: EXPERIMENTAL
Intervention: TT-173
Number of subjects: 71
Study 28126447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 26214071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with GBNs (13 g/day for three months)
Number of subjects: 91
Study 26214071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 23356951 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality‐based vocational training group (VRG)
Number of subjects: 95
Study 23356951 — intervention group
Group type: COMPARATOR
Intervention: Virtual reality‐based vocational training group (VRG) and therapist‐administered group (TAG)
Number of subjects: 95
Study 21679171 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care placement by 15 months
Number of subjects: 174
Study 21679171 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care placement from 15 to 24 months
Number of subjects: 174
Study 21679171 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care placement after 24 months
Number of subjects: 174
Study 18299865 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida albicans
Number of subjects: 1073
Study 18299865 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis
Number of subjects: 1073
Study 16958945 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI‐assisted BDZ‐reduction group (10‐20 mg of paroxetine, n = 22)
Number of subjects: 66
Study 16958945 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple BDZ‐reduction group (no paroxetine, n = 23)
Number of subjects: 66
Study 16958945 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no BDZ‐reduction, n = 21)
Number of subjects: 66
Study 15534491 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A2-restricted peptide (ESO-1:165V)
Number of subjects: 0
Study 15534491 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DP4-restricted peptide (NY-ESO-1:161-180)
Number of subjects: 0
Study 15534491 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination with both peptides
Number of subjects: 0
Study 15534491 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine given daily for 4 days
Number of subjects: 0
Study 15534491 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A2-restricted epitope
Number of subjects: 0
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg of intraarticular clonidine with subcutaneous saline
Number of subjects: 84
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of intraarticular neostigmine with subcutaneous saline
Number of subjects: 84
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg of intraarticular clonidine and 500 microg of neostigmine with subcutaneous saline
Number of subjects: 84
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg of intraarticular clonidine with 500 microg of subcutaneous neostigmine
Number of subjects: 84
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg of intraarticular neostigmine with 150 microg of subcutaneous clonidine
Number of subjects: 84
Study 11464354 — intervention group
Group type: COMPARATOR
Intervention: intraarticular and subcutaneous isotonic saline
Number of subjects: 84
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 84
Study 11464354 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 84
Study 9059319 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary isometric contraction (40% of maximum voluntary contraction)
Number of subjects: 10
Study 9059319 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐voluntary electrically evoked contractions (40% of maximum voluntary contraction)
Number of subjects: 10
Study 7893580 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 100 mg
Number of subjects: 10
Study 7893580 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg
Number of subjects: 10
Study 3556193 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 160 mg
Number of subjects: 31
Study 3556193 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 320 mg
Number of subjects: 31
Study 3556193 — intervention group
Group type: COMPARATOR
Intervention: Oros oxprenolol 10/170 mg
Number of subjects: 31
Study 29325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (higher reward for behaviour)
Number of subjects: 207
Study 29325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (lower covert restriction)
Number of subjects: 207
Study 29325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (increased structured meal timing)
Number of subjects: 207
Study 29325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (overt restriction)
Number of subjects: 207
Study 29325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (covert restriction)
Number of subjects: 207
Study 29325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Family meal setting
Number of subjects: 207
Study 27333235 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant
Number of subjects: 30
Study 24363363 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin dissolved in human milk at a concentration of 50 mg/mL
Number of subjects: 16
Study 24363363 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin dissolved in water at a concentration of 50 mg/mL
Number of subjects: 16
Study 24373369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy
Number of subjects: 41
Study 24373369 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Number of subjects: 41
Study 20035226 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg kg(‐1)
Number of subjects: 92
Study 20035226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg kg(‐1) + low-dose oral ketamine 2 mg kg(‐1)
Number of subjects: 92
Study 17600651 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 0
Study 17600651 — intervention group
Group type: COMPARATOR
Intervention: Group treatment
Number of subjects: 0
Study 16815744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem-MR 12.5mg
Number of subjects: 212
Study 16815744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 12815569 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 3091
Study 10768021 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 cd.m‐2 surround
Number of subjects: 4
Study 10768021 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 cd.m‐2 surround
Number of subjects: 4
Study 10768021 — intervention group
Group type: COMPARATOR
Intervention: 3-30 cd.m‐2 surrounds
Number of subjects: 4
Study 10768021 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher luminance surrounds
Number of subjects: 4
Study 7721443 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (Estraderm-TTS-50) and norethisterone acetate (NETA)
Number of subjects: 26
Study 7721443 — intervention group
Group type: COMPARATOR
Intervention: Control (no HRT)
Number of subjects: 26
Study 2707399 — intervention group
Group type: COMPARATOR
Intervention: Oxygen concentrators only (OC)
Number of subjects: 159
Study 2707399 — intervention group
Group type: EXPERIMENTAL
Intervention: Small oxygen cylinders plus OC (B1)
Number of subjects: 159
Study 2707399 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oxygen (B2)
Number of subjects: 159
Study 2707399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy (both groups)
Number of subjects: 159
Study 17642108 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lithium chloride (0.72 mEq/kg/day)
Number of subjects: 68
Study 17642108 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose lithium chloride (0.5 mEq/kg/day)
Number of subjects: 68
Study 17642108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lithium chloride (0.24 mEq/kg/day)
Number of subjects: 68
Study 17642108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30466310 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic linkage using limited patient identifiers from the Canadian Cancer Trials Group and administrative data from the Institute for Clinical Evaluative Sciences.
Number of subjects: 293
Study 30466310 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic linkage between Canadian Cancer Trials Group data and Institute for Clinical Evaluative Sciences data.
Number of subjects: 293
Study 30466310 — intervention group
Group type: COMPARATOR
Intervention: Institute for Clinical Evaluative Sciences data.
Number of subjects: 293
Study 30466310 — intervention group
Group type: COMPARATOR
Intervention: Administrative databases during clinical trial conduct.
Number of subjects: 293
Study 28526329 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention aimed at reducing sedentary time through guided goal setting and behaviour change techniques.
Number of subjects: 70
Study 28526329 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention consisting of weekly phone calls for 6 weeks.
Number of subjects: 70
Study 25616919 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel
Number of subjects: 62
Study 25616919 — intervention group
Group type: COMPARATOR
Intervention: 600 mg clopidogrel
Number of subjects: 62
Study 23380072 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine Mouthwash (0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium fluoride)
Number of subjects: 90
Study 23380072 — intervention group
Group type: COMPARATOR
Intervention: Negative Control Mouthwash (ordinary mouthwash without any active ingredients)
Number of subjects: 90
Study 21784373 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (1g niacin/20 mg laropiprant) for the first 4 weeks, then 2 tablets once daily thereafter
Number of subjects: 785
Study 21784373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 785
Study 19160734 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17225939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (6.0 Gy total, 1.0 Gy per fraction, 2 fractions per week for 3 weeks)
Number of subjects: 130
Study 17225939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (3.0 Gy total, 0.5 Gy per fraction, 2 fractions per week)
Number of subjects: 130
Study 17225939 — intervention group
Group type: COMPARATOR
Intervention: Comparison of response to RT between both groups
Number of subjects: 130
Study 15452520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine by iontophoresis
Number of subjects: 90
Study 15452520 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 90
Study 15452520 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative procedure
Number of subjects: 90
Study 11685184 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stent implantation
Number of subjects: 77
Study 10933472 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis patients with major mood disorders
Number of subjects: 65
Study 10933472 — intervention group
Group type: COMPARATOR
Intervention: Polyneuropathy patients
Number of subjects: 65
Study 7987192 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly role-specified (HRS) version of the alcohol prevention programme
Number of subjects: 955
Study 7987192 — intervention group
Group type: EXPERIMENTAL
Intervention: Less role-specified (LRS) version of the alcohol prevention programme
Number of subjects: 955
Study 7987192 — intervention group
Group type: COMPARATOR
Intervention: Non-treated comparison condition
Number of subjects: 955
Study 7987192 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall programme effect across all dependent variables
Number of subjects: 955
Study 3540135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene (DNCB) and nickel exposure
Number of subjects: 0
Study 3540135 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin exposure
Number of subjects: 0
Study 3540135 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of sensitization to DNCB
Number of subjects: 0
Study 3540135 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31351901 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training (IG)
Number of subjects: 30
Study 31351901 — intervention group
Group type: COMPARATOR
Intervention: Conventional eccentric training (CG)
Number of subjects: 30
Study 30005744 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (2.5 mg twice a day)
Number of subjects: 17
Study 30005744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg twice a day)
Number of subjects: 17
Study 30005744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of midodrine and pyridostigmine
Number of subjects: 17
Study 30005744 — intervention group
Group type: COMPARATOR
Intervention: Classic OH (control group, n=87)
Number of subjects: 17
Study 27028612 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (25-30 sessions over 10 weeks)
Number of subjects: 0
Study 27028612 — intervention group
Group type: COMPARATOR
Intervention: Control period (10 weeks)
Number of subjects: 0
Study 27028612 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (10 weeks follow-up after training)
Number of subjects: 0
Study 25007091 — intervention group
Group type: EXPERIMENTAL
Intervention: pSG2.HIVconsv DNA vaccine
Number of subjects: 32
Study 25007091 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv vaccine
Number of subjects: 32
Study 25007091 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv vaccine
Number of subjects: 32
Study 25007091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 25007091 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdV-63
Number of subjects: 32
Study 22311342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 171
Study 22311342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 19931416 — intervention group
Group type: EXPERIMENTAL
Intervention: IRSCE at 14.0 g (7.8 g of inulin)
Number of subjects: 53
Study 19931416 — intervention group
Group type: EXPERIMENTAL
Intervention: IRSCE at 8.1 g/d (5.0 g of inulin)
Number of subjects: 53
Study 19931416 — intervention group
Group type: COMPARATOR
Intervention: Control (sucrose 10 g and 8.1 g/d)
Number of subjects: 53
Study 17550987 — intervention group
Group type: EXPERIMENTAL
Intervention: MS patients
Number of subjects: 147
Study 19223885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pico-Salax plus bisacodyl
Number of subjects: 315
Study 19223885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pico-Salax alone
Number of subjects: 315
Study 19223885 — intervention group
Group type: COMPARATOR
Intervention: Oral sodium phosphate
Number of subjects: 315
Study 15177801 — intervention group
Group type: EXPERIMENTAL
Intervention: Targets presented to the same visual field (VF)
Number of subjects: 1
Study 15177801 — intervention group
Group type: EXPERIMENTAL
Intervention: Targets presented to different visual fields (VFs)
Number of subjects: 1
Study 15177801 — intervention group
Group type: EXPERIMENTAL
Intervention: Second target presented to the right hemisphere (RH)
Number of subjects: 1
Study 11494545 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-ribavirin combination therapy
Number of subjects: 0
Study 11494545 — intervention group
Group type: COMPARATOR
Intervention: IFN monotherapy
Number of subjects: 0
Study 9470077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (SB) 400 micrograms every 4 hours
Number of subjects: 19
Study 9470077 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salmeterol (SM) 100 micrograms every 12 hours
Number of subjects: 19
Study 8271352 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate-based TPN (8.5% amino acids, 50% dextrose, 7.5% of total calories from lipids)
Number of subjects: 43
Study 8271352 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric lipid-based TPN (8.5% amino acids, 30% dextrose, 40% of total calories from lipids)
Number of subjects: 43
Study 8271352 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate-based TPN (CHO)
Number of subjects: 43
Study 8271352 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric lipid-based TPN (LIP-CHO)
Number of subjects: 43
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: sweet acidophilus milk (SAM) made with sonicated cells
Number of subjects: 14
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: yogurt
Number of subjects: 14
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: heated yogurt
Number of subjects: 14
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: yogurt plus lactose
Number of subjects: 14
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: heated yogurt plus lactase
Number of subjects: 14
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: milk
Number of subjects: 14
Study 3103415 — intervention group
Group type: EXPERIMENTAL
Intervention: sweet acidophilus milk (SAM)
Number of subjects: 14
Study 31361019 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-181 (100-600 mg BID)
Number of subjects: 638
Study 29584536 — intervention group
Group type: EXPERIMENTAL
Intervention: RTclin test on days 1, 2, 3, 7, and 60
Number of subjects: 112
Study 29584536 — intervention group
Group type: COMPARATOR
Intervention: RTclin test on days 1 and 60
Number of subjects: 112
Study 28784179 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (n=10 CCS), bi-weekly sessions over 8 months covering making social contacts, problem solving, emotional self-regulation, emotional expression and recognition.
Number of subjects: 362
Study 28784179 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n=9 CCS).
Number of subjects: 362
Study 25705899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 60
Study 25705899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25488448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficient (<12 ng/ml)
Number of subjects: 266
Study 25488448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (12 to <20 ng/ml)
Number of subjects: 266
Study 25488448 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D sufficient (≥ 20 ng/ml)
Number of subjects: 266
Study 22974257 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic consultation in the workplace
Number of subjects: 280
Study 22974257 — intervention group
Group type: COMPARATOR
Intervention: Conventional regional outpatient clinic care
Number of subjects: 280
Study 19323613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine ER 30 mg
Number of subjects: 504
Study 19323613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine ER 15 mg
Number of subjects: 504
Study 19323613 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine immediate release (CIR) 10 mg
Number of subjects: 504
Study 19323613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 17716961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine surgery for repair of fetal myelomeningocele
Number of subjects: 0
Study 17716961 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair through a hysterotomy
Number of subjects: 0
Study 15050506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragon boat training for 10 weeks
Number of subjects: 0
Study 15050506 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control subjects
Number of subjects: 0
Study 11304861 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of estriol (1 mg/d) and pelvic floor muscle exercise (PFME)
Number of subjects: 66
Study 11304861 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercise (PFME) alone
Number of subjects: 66